GLP1R and cancer: A common theme emerging from the preclinical studies of GLP-1R agonists and cancer is the potential to promote antitumor immune cell phenotypes (47, 57, 58, 66, 82), including in lean mice that were not given a high-fat diet (47, 66, 82).